A device comprising a housing having a handle end and a treatment end. The treatment end is configured to provide an antimicrobial treatment and a heat treatment. The treatment end comprises an applicator having an applicator surface for providing at least the heat treatment. The device includes a heat generation unit configured to heat the applicator surface in use, a source of antimicrobial agent, and a control unit operatively connected to at least the heat generation unit for controlling the heat generation unit. The device can be a hand-held device and used to apply topical treatment to a treatment area of a subject.

Methods of maintaining narrow residence time distributions in continuous flow systems, particularly applicable to virus inactivation such as during a protein purification process. Fluid sample is introduced into an axial flow channel and caused to flow therein in discrete packets or zones to minimize residence time distribution and axial dispersion. Embodiments described herein obviate or minimize the need for using large tanks or reservoirs for performing virus inactivation during a protein purification process; reduce the overall time required for virus inactivation, and/or reduce the overall physical space required to perform the virus inactivation operation during a protein purification process, which in turn reduces the overall footprint for the purification process.

The present invention relates to a method to prepare pharmaceutical compositions of sugammadex, to pharmaceutical compositions of sugammadex and uniform pharmaceutical batches of said compositions.

A method for preparing a filtered beverage includes filtering a raw beverage using a cross-flow ultrafiltration device to produce a solids fraction and a liquid fraction; heating the solids fraction to a temperature of 60° C. or greater to produce a pasteurized solids fraction; microfiltering the liquid fraction through a microfilter having a size cut-off of 1 μm or smaller to produce a microfiltered liquid fraction; and combining the pasteurized solids fraction and the microfiltered liquid fraction to result in the filtered beverage.

A process for minimizing formation of a highest degradation product during moist heat sterilization of a drug solution of an oxidation susceptible active pharmaceutical ingredient (API) is provided, wherein the water is not deoxygenated and a nitrogen blanket is not used during formulation, or the formulation is stored in ambient conditions in the polymer bag and autoclaved. The highest degradation product in the parenteral drug product is less than 0.1% by weight of a labeled amount of the oxidation susceptible API in the parenteral drug product.

The invention discloses an identification method, a constant temperature aseptic storage method and a sterilization container, and relates to the technical field of sterilization. The identification method maintains the sterilized article at a preset constant temperature after the sterilization is finished, and utilizes the temperature of the sterilized article for identifying whether the sterilized article is sterilized. The constant temperature aseptic storage method is to control the illumination device and the heating air duct of the sterilization container to run in a low-power operation, and continuously release a small amount of ultraviolet light and a small amount of hot air to the article storage cavity of the sterilization container so as to maintain the sterilized article at a preset constant temperature and aseptic condition. The sterilization container is capable of performing the identification method and the constant temperature sterilization method.

The invention relates to a self-disinfecting object having a contact surface of a substrate provided for contact with a human body part, wherein the contact surface is at least regionally heatable.

Disclosed herein are soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. Some of the hyaluronic acid-based compositions can include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. Compared to conventional compositions that include lidocaine, some of the hyaluronic acid-based compositions disclosed herein can have an enhanced stability, for example, when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such compositions are also provided.

A continuous differential-pressure steam sterilization system for a powder, and belongs to the field of material sterilization includes: a superheated steam generation system, a steam pressure and flow rate control system, a quantitative feeding system, an instantaneous differential-pressure sterilization system, a dust explosion suppression system, a sterile cooling system, a primary gas-solid separation system, a secondary gas-solid separation system, a sterile storage system, a steam recovery and reheating system, and a condensate recovery system. The continuous differential-pressure steam sterilization system shortens the thermal contact time and mainly accumulates the heat on the surface of the powder, rather than in the center of the powder, which reduces the damage to the nutritional quality of the powder. Comprehensive treatment methods such as superheated steam, temperature compensation and non-sticky inner lining are adopted to reduce the problem of powder binding, agglomeration, and even blocking in the pipe of the system.

Systems and methods are provided for automated detection and disinfection of microbes in autonomous vehicles, to prevent possible transmission of diseases or illness to subsequent users. Automated detection and disinfection of a vehicle includes autonomously scanning various parts of the autonomous vehicle for microbes, selecting a disinfectant based on detected microbes, and autonomously disinfecting at least a portion of the autonomous vehicle.